Roche's Genentech Wins FDA Approval for Enspryng to Treat Thyroid Eye Disease
Roche unit Genentech secured FDA approval for Enspryng to treat adults with thyroid eye disease. Enspryng becomes the first and only at-home subcutaneous treatment for the condition, administered by patients or caregivers following training. In SatraGO-2, proptosis response reached 52.9% with Enspryng versus 23.4% with